Luyan Pharma Co.,Ltd. (SHE:002788)
China
· Delayed Price · Currency is CNY 8.37
+0.02 (0.24%)
May 30, 2025, 2:45 PM CST
Luyan Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 333.19 | 345.64 | 363.53 | 345.16 | 305.87 | 266.63 | Upgrade
|
| Depreciation & Amortization | 129.15 | 129.15 | 120.61 | 112.78 | 112.77 | 48.46 | Upgrade
|
| Other Amortization | 13.27 | 13.27 | 9.81 | 10.89 | 11.87 | 11.91 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.17 | -0.17 | -0.28 | -0.13 | 0.53 | -0.03 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.09 | 0.09 | 0.13 | 0.03 | 3.6 | 19.46 | Upgrade
|
| Loss (Gain) From Sale of Investments | 18.73 | 18.73 | 12.16 | 6.92 | -4.78 | -2.48 | Upgrade
|
| Provision & Write-off of Bad Debts | -3.53 | -3.53 | 12.95 | 32.39 | 23.61 | 12.38 | Upgrade
|
| Other Operating Activities | 253.16 | 215.91 | 228.19 | 244.96 | 201.89 | 178.51 | Upgrade
|
| Change in Accounts Receivable | -400.02 | -400.02 | 473.89 | -1,120 | -998.54 | -377.97 | Upgrade
|
| Change in Inventory | -292.39 | -292.39 | -29.27 | -276.23 | -253.58 | -279.5 | Upgrade
|
| Change in Accounts Payable | 560.47 | 560.47 | 129.3 | 886.8 | 232.66 | 190.05 | Upgrade
|
| Operating Cash Flow | 602.29 | 577.48 | 1,309 | 232.19 | -372.02 | 60.39 | Upgrade
|
| Operating Cash Flow Growth | -44.72% | -55.89% | 463.82% | - | - | - | Upgrade
|
| Capital Expenditures | -304.55 | -361.12 | -529.21 | -327.58 | -243.49 | -170.74 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.41 | 0.44 | 0.43 | 0.35 | 0.3 | 1.88 | Upgrade
|
| Cash Acquisitions | -0.15 | -0.15 | - | - | -1.86 | -9.54 | Upgrade
|
| Divestitures | - | - | 7.46 | - | -0.02 | -1.59 | Upgrade
|
| Investment in Securities | -4.61 | -8.9 | -12.92 | -2 | -31 | - | Upgrade
|
| Other Investing Activities | 17.24 | - | - | 0.08 | 0.92 | 1.27 | Upgrade
|
| Investing Cash Flow | -291.66 | -369.73 | -534.24 | -329.16 | -273.36 | -178.72 | Upgrade
|
| Long-Term Debt Issued | - | 8,943 | 8,945 | 8,680 | 6,654 | 5,374 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -1.46 | -33.42 | Upgrade
|
| Long-Term Debt Repaid | - | -8,928 | -9,254 | -8,158 | -5,823 | -5,116 | Upgrade
|
| Total Debt Repaid | -8,759 | -8,928 | -9,254 | -8,158 | -5,824 | -5,150 | Upgrade
|
| Net Debt Issued (Repaid) | -4.81 | 14.55 | -308.61 | 522.09 | 830.02 | 224.67 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 331.82 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -11.4 | -1.6 | Upgrade
|
| Common Dividends Paid | -325.81 | -323.83 | -340.1 | -331.07 | -250.08 | -213.13 | Upgrade
|
| Other Financing Activities | -12.42 | -19.28 | -60.27 | -6.55 | -92.85 | -28.89 | Upgrade
|
| Financing Cash Flow | -343.03 | -328.56 | -708.99 | 184.46 | 475.68 | 312.88 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.18 | 0.21 | 0.82 | 2.39 | -0.71 | -1.35 | Upgrade
|
| Net Cash Flow | -32.22 | -120.58 | 66.71 | 89.87 | -170.4 | 193.21 | Upgrade
|
| Free Cash Flow | 297.74 | 216.36 | 779.91 | -95.4 | -615.51 | -110.35 | Upgrade
|
| Free Cash Flow Growth | -47.27% | -72.26% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 1.45% | 1.06% | 3.93% | -0.49% | -3.51% | -0.71% | Upgrade
|
| Free Cash Flow Per Share | 0.76 | 0.56 | 2.02 | -0.25 | -1.59 | -0.31 | Upgrade
|
| Cash Income Tax Paid | 388.8 | 384.88 | 377.42 | 353.85 | 342.77 | 281.61 | Upgrade
|
| Levered Free Cash Flow | 116.57 | 67.86 | 409.7 | -195.36 | -889.06 | -400.99 | Upgrade
|
| Unlevered Free Cash Flow | 244 | 197.04 | 548.98 | -58.42 | -770.14 | -298.54 | Upgrade
|
| Change in Net Working Capital | 11.79 | 11.92 | -513.47 | 293.47 | 1,027 | 532.03 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.